Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 8/20 | 0.52 |
| ▸ | NPY1R | P25929 | 6/20 | 0.52 |
| ▸ | NPY2R | P49146 | 4/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | YARS1 | P54577 | 2/20 | 0.49 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31253372 | 0.98 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RERAP2 | |
| Kyotorphin SCHEMBL248289 | 0.91 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5R | |
| D[-Arg-2]Kyotorphan Acetate SCHEMBL29780328 | 0.91 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5R | |
| Kyotorphin SCHEMBL248288 | 0.91 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5R | |
| Kyotorphin SCHEMBL2889815 | 0.91 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL27757798 | 0.90 | C3AR1 (0.55) | ERAP2LNPEPSLC7A5C3AR1 | |
| SCHEMBL6047680 | 0.90 | C3AR1 (0.55) | ERAP2LNPEPSLC7A5C3AR1 | |
| SCHEMBL1711684 | 0.90 | C3AR1 (0.55) | ERAP2LNPEPSLC7A5C3AR1 | |
| SCHEMBL10618982 | 0.89 | ERAP2 (0.53) | NPY4RNPY1RNPY2RNPY5RERAP2 | |
| SCHEMBL30198606 | 0.89 | NPY4R (0.66) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076960-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250387350-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12419846-B2 | Biomarkers of METAP2 inhibitors and applications thereof | SYNDEVRX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250288606-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-3858385-B1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20230404963-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CD4/6 INHIBITORS FOR THE TREATMENT OF CANCER | SYNDEVRX, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-4243807-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER | Syndevrx, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-11612577-B2 | Biomarkers of METAP2 inhibitors and applications thereof | SYNDEVRX, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220280470-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUCTION | SYNDEVRX, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022103834-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER | SYNDEVRX, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-11304944-B2 | MetAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| CN-114225045-A | Treatment of tumors caused by metabolic dysfunction | 辛德弗雷克斯公司 | 2022-03-25 | — | — | CN | disclosed |
| US-11273142-B2 | Treatment for tumors driven by metabolic dysfunction | SYNDEVRX, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| CN-107158398-B | Polymer-conjugated MetAP2 inhibitors and methods of treatment using the same | 辛德弗雷克斯公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230404963-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CD4/6 INHIBITORS FOR THE TREATMENT OF CANCER | CDK6, MPHOSPH6, CD4 | NPY4R 4797/4885NPY1R 4876/4885NPY2R 4829/4885 |
| US-20220280470-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUCTION | PCK2, PC, GOT2 | NPY4R 3581/4885NPY1R 4133/4885NPY2R 3524/4885 |
| US-20260076960-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, METAP1, LNPEP | NPY4R 578/4885NPY1R 564/4885NPY2R 435/4885 |
| US-11273142-B2 | Treatment for tumors driven by metabolic dysfunction | PCK2, GOT2, PC | NPY4R 3409/4885NPY1R 3944/4885NPY2R 3360/4885 |
| US-20250387350-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, TGFB2, IGF2BP2 | NPY4R 2010/4885NPY1R 2329/4885NPY2R 1850/4885 |
| US-11304944-B2 | MetAP2 inhibitors and methods of treating obesity | METAP2, ADIPOR2, METAP1 | NPY4R 1442/4885NPY1R 1429/4885NPY2R 1142/4885 |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | NPY4R 4391/4885NPY1R 4451/4885NPY2R 4032/4885 |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | NPY4R 4221/4885NPY1R 3842/4885NPY2R 3570/4885 |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | NPY4R 1442/4885NPY1R 1429/4885NPY2R 1142/4885 |
| US-20250288606-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | NPY4R 4221/4885NPY1R 3842/4885NPY2R 3570/4885 |
| US-11612577-B2 | Biomarkers of METAP2 inhibitors and applications thereof | METAP2, METAP1, PCK2 | NPY4R 4383/4885NPY1R 4452/4885NPY2R 4023/4885 |
| US-12419846-B2 | Biomarkers of METAP2 inhibitors and applications thereof | METAP2, METAP1, PEBP1 | NPY4R 4391/4885NPY1R 4451/4885NPY2R 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.